Patents by Inventor Walter Low

Walter Low has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20220267367
    Abstract: Methods of preventing or retarding or reversing or abolishing the onset of Parkinson's and other neurodegenerative diseases are discussed.
    Type: Application
    Filed: March 24, 2022
    Publication date: August 25, 2022
    Inventors: Walter Low, Clifford Steer, Michael D. Finch, Cyrus B. Munshi
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20210346473
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: March 25, 2021
    Publication date: November 11, 2021
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20210122780
    Abstract: Methods of preventing or retarding or reversing or abolishing the onset of Parkinson's and other neurodegenerative diseases are discussed.
    Type: Application
    Filed: March 29, 2019
    Publication date: April 29, 2021
    Inventors: Walter Low, Clifford Steer, Michael D. Finch, Cyrus B. Munshi
  • METHODS TO TREAT POMPE DISEASE USING A RECOMBINANT ADENO-ASSOCIATED VIRUS
    Publication number: 20210085759
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: December 10, 2020
    Publication date: March 25, 2021
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20210085760
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: December 10, 2020
    Publication date: March 25, 2021
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20190298812
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: June 11, 2019
    Publication date: October 3, 2019
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • Deuterated bile acids
    Patent number: 10144758
    Abstract: This disclosure relates to deuterated bile acid compositions. A deuterated compound is selected from the bile acids such as ursodeoxycholic acid (UDCA) and tauroursodeoxycholic acid (TUDCA), and their derivatives, analogs and salts. At least one of the hydrogen atoms in the compound is replaced with deuterium. Also disclosed are pharmaceutical compositions and methods of using the deuterated bile acids.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: December 4, 2018
    Assignee: Metselex, Inc.
    Inventors: Michael D Finch, Walter Low, Clifford Steer, Cyrus B. Munshi, Cecilia M. P. Rodrigues, Susana Dias Lucas de Oliveira
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20180271955
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • METHODS TO TREAT POMPE DISEASE USING A RECOMBINANT ADENO-ASSOCIATED VIRUS
    Publication number: 20180271956
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: May 31, 2018
    Publication date: September 27, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • METHODS TO TREAT CEROID LIPOFUSCINOSIS USING A RECOMBINANT ADENO-ASSOCIATED VIRUS
    Publication number: 20180271957
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: May 31, 2018
    Publication date: September 27, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20180264090
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 20, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • METHODS TO TREAT MUCOPOLYSACCHARIDE TYPE II OR DEFICIENCY IN IDURONATE-2-SULFATASE USING A RECOMBINANT ADENO-ASSOCIATED VIRUS ENCODING IDURONATE-2-SULFATASE
    Publication number: 20180099030
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: September 27, 2017
    Publication date: April 12, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20180036388
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: September 27, 2017
    Publication date: February 8, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks
  • DEUTERATED BILE ACIDS
    Publication number: 20180030084
    Abstract: This disclosure relates to deuterated bile acid compositions. A deuterated compound is selected from the disclosed groups of bile acids and their derivatives, analogs and salts. At least one of the hydrogen atoms in the compound is replaced with deuterium.
    Type: Application
    Filed: July 17, 2017
    Publication date: February 1, 2018
    Inventors: Michael D. Finch, Walter Low, Clifford Steer, Cyrus B. Munshi, Cecilia M.P. Rodrigues, Susana Dias Lucas de Oliveira
  • Methods to treat mucopolysaccharide type I or deficiency in alpha-L-iduronidase using a recombinant adeno-associated virus encoding alpha-L-iduronidase
    Patent number: 9827295
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: November 28, 2017
    Assignees: Regents of the University of Minnesota, REGENXBIO Inc.
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • Deuterated bile acids
    Patent number: 9708362
    Abstract: This disclosure relates to deuterated bile acid compositions. A deuterated compound is selected from the disclosed groups of bile acids and their derivatives, analogs and salts. At least one of the hydrogen atoms in the compound is replaced with deuterium.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: July 18, 2017
    Assignee: Metselex, Inc.
    Inventors: Michael D. Finch, Walter Low, Clifford Steer, Cyrus B. Munshi, Cecilia Rodrigues, Susana Dias Lucas de Oliveria
  • Therapeutic composition for treatment of glioblastoma
    Patent number: 9662377
    Abstract: The present invention is directed to compositions and methods for treating an animal diagnosed with Glioblastoma multiforme (GBM).
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: May 30, 2017
    Assignee: REGENTS OF THE UNIVERSITY OF MINNEOSTA
    Inventors: Michael Raymond Olin, John R. Ohlfest, Walter Low
  • THERAPEUTIC COMPOSITION FOR TREATMENT OF GLIOBLASTOMA
    Publication number: 20160263207
    Abstract: The present invention is directed to compositions and methods for treating an animal diagnosed with Glioblastoma multiforme (GBM).
    Type: Application
    Filed: April 21, 2016
    Publication date: September 15, 2016
    Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Michael Raymond Olin, John R. Ohlfest, Walter Low
  • DEUTERATED BILE ACIDS
    Publication number: 20160168189
    Abstract: This disclosure relates to deuterated bile acid compositions. A deuterated compound is selected from the disclosed groups of bile acids and their derivatives, analogs and salts. At least one of the hydrogen atoms in the compound is replaced with deuterium.
    Type: Application
    Filed: February 24, 2016
    Publication date: June 16, 2016
    Applicant: Metselex, Inc.
    Inventors: Michael D. Finch, Walter Low, Clifford Steer, Cyrus B. Munshi, Cecilia Rodrigues, Susana Dias Lucas de Oliveria
  • Therapeutic composition for treatment of glioblastoma
    Patent number: 9364505
    Abstract: The present invention is directed to compositions and methods for treating an animal diagnosed with Glioblastoma multiforme (GBM).
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: June 14, 2016
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Michael Raymond Olin, Walter Low, John R. Ohlfest, Karen H. Ohlfest